Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lead-in observational FIX prophylaxis study in adult hemophilia B
NL-OMON48660Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Dec 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor ix in hemophilia B (HB), sponsored by Pfizer. Primary endpoint: Annualized bleeding rate. Planned start Dec 2018; status: withdrawn.
02
Drugs
coagulation factor ix
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON48660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48660.